Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review
Por:
Bossi, P, Kiyota, N, Mesia, R, Rosenberg, AJ, Martino, R, Posorske, CF, Salmio, S, Schroeder, A and Yom, SS
Publicada:
1 oct 2025
Ahead of Print:
1 ago 2025
Resumen:
Background: Patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are treated with curative intent. Treatment guidelines recommend tumor resection, followed by adjuvant radiotherapy or chemoradiotherapy in patients with high risk of disease recurrence, or definitive chemoradiotherapy in patients who do not undergo surgery. When indicated, concurrent cisplatin provides benefit over radiotherapy alone but is highly toxic. In this systematic literature review, we review adverse event (AE) profiles of cisplatin based chemoradiotherapy in patients with LA SCCHN and synthesize AE management strategies based on expert clinical opinion. Methods: PubMed and Google Scholar were searched for relevant articles published between January 1, 2000, and January 9, 2024. Eligible articles characterized AE profiles associated with cisplatin-based chemoradiotherapy. Data on the percentage of patients with AEs were compared across cisplatin regimens. Results: We reviewed 53 articles reporting on 51 studies. Cisplatin 40 mg/m2 weekly (QW) was more tolerable than cisplatin 100 mg/m2 every 3 weeks (Q3W), incurring less acute grade 3-5 neutropenia, hepatotoxicity, nephrotoxicity and related electrolyte imbalances, and tinnitus in the postoperative setting, but cisplatin QW led to more frequent thrombocytopenia and pain. Conclusion: The relative efficacy of cisplatin Q3W versus QW remains under investigation. Cisplatin QW inherently increases the cumulative cisplatin dose more gradually, which may help in managing certain AEs. Treatment guidelines should be updated on the management of challenging AEs, including more detailed criteria on topics such as management of kidney failure including dialysis and timing of feeding tube placement.
Filiaciones:
Bossi, P:
Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Pieve Emanuele, Milan, Italy
IRCCS Humanitas Res Hosp, Milan, Italy
Kiyota, N:
Kobe Univ Hosp, Dept Med Oncol & Hematol, Canc Ctr, 7-5-2 Kusuoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
:
Germans Trias & Pujol Res Inst IGTP, Catalan Inst Oncol ICO, Med Oncol Dept, Badalona Appl Res Grp Oncol B ARGO, Carretera Can Ruti,Cami Escoles S-N, Badalona 08916, Spain
Rosenberg, AJ:
Univ Chicago Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
Martino, R:
Univ Toronto, Dept Otolaryngol Head & Neck Surg, 600 Univ Ave 401, Toronto, ON M5G 1X5, Canada
Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada
Univ Toronto, Dept Speech Language Pathol, Toronto, ON, Canada
Posorske, CF:
Mayo Clin, Dept Med Oncol, 200 1st St NW, Rochester, MN 55905 USA
Salmio, S:
Merck Healthcare KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany
Schroeder, A:
Merck Healthcare KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany
Yom, SS:
Univ Calif San Francisco, Dept Radiat Oncol, 1825 4th St, San Francisco, CA 94143 USA
hybrid
|